Accès ouvert

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults

Article scientifique 2025 Anglais

Résumé

Background: Lassa fever (LF) is an acute viral hemorrhagic illness endemic to West Africa, with no licensed vaccines or targeted treatments available, highlighting a critical gap in global health preparedness. T cell-mediated immunity plays a central role in viral control and survival. Synthetic DNA vaccines offer a promising strategy to induce both humoral and cellular immunity against LF. Methods: A Phase 1b, randomized, double-blind, placebo-controlled trial was conducted to assess the safety, tolerability, and immunogenicity of INO-4500, a DNA vaccine encoding the Lassa virus (Josiah strain) glycoprotein precursor (GPC). A total of 220 healthy adults were randomized to receive either 1 mg or 2 mg of INO-4500 (intervention), or placebo, administered intradermally (ID) followed by electroporation (EP) at Day 0 and Week 4. Safety was evaluated through Week 48. Primary immunogenicity endpoints included humoral and cellular immune responses at multiple timepoints post-vaccination. Results: INO-4500 was well tolerated, with no Grade 3 or higher treatment-emergent adverse events (TEAEs) deemed to be related to the intervention; 88.6% of all TEAEs were Grade 1. No cases of attributable hearing loss were reported. INO-4500 groups demonstrated statistically significant increases in Lassa virus GPC-specific binding antibodies at Weeks 6 and 12 compared to placebo, with the 2 mg group eliciting the strongest responses. T cell responses remained elevated above baseline through Week 48 in both INO-4500 groups, indicating durable cellular immunity. Conclusions: DNA vaccine INO-4500 was well tolerated and elicited durable humoral and cellular immune responses in healthy adults. These findings support further clinical development of INO-4500 as a potential preventive vaccine to reduce LF-associated morbidity and mortality in endemic regions. Clinical Trial Registration: https://clinicaltrials.gov, identifier NCT04093076.

Citer ce document

Koram, K., Walker, K., Orizu, B., Marrero, I., Boyer, J., Yang, S., Broderick, K., Kusi, K., Kyei‐Baafour, E., Ofori, E., Pobee, A., Adu-Amankwah, S., Amoakoh‐Coleman, M., Amoakoh, H., Abuaku, B., Badji, E., Ntiri, M., Quaye, L., Morrow, M., Sylvester, A., Reuschel, E., Gillespie, E., Liebowitz, D., Humeau, L. (2025). Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults. https://doi.org/10.3389/fimmu.2025.1658549

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Auteur(s)

Kwadwo Koram Kathleen A. Walker Bonaventure Orizu Idania Marrero Jean Boyer ShuPing Yang Kate E. Broderick Kwadwo Asamoah Kusi Eric Kyei‐Baafour Ebenezer Addo Ofori Abigail Naa Adjorkor Pobee Susan Adu-Amankwah Mary Amoakoh‐Coleman Hannah Brown Amoakoh Benjamin Abuaku Edem Badji Michael Ntiri Lydia Quaye Matthew P. Morrow Albert J. Sylvester Emma L. Reuschel Elisabeth B. Gillespie David Neal Liebowitz Laurent Humeau

Statistiques

Consultations : 1

Téléchargements : 0